Bio-Rad Laboratories, Inc. BIO.B Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Clinical Diagnostics | $363.6M-14.5% | $425.3M+8.7% | $391.2M+0.6% | $388.8M+9.0% | $356.8M-9.1% | |
| Life Science | $228.5M-14.7% | $267.9M+2.3% | $261.8M-0.4% | $262.8M+15.0% | $228.6M-16.9% | |
| Gross Profit by Business | ||||||
| Clinical Diagnostics | $181.8M-15.3% | $214.7M+8.7% | $197.5M+0.3% | $197M+10.9% | $177.6M-4.4% | |
| Life Science | $127.6M-2.2% | $130.5M-10.6% | $145.9M-1.6% | $148.3M+15.5% | $128.4M-17.8% | |
| Total Assets by Business | ||||||
| Clinical Diagnostics | $468.8M+3.9% | $451.4M-4.4% | $472.3M-3.4% | $489M+1.5% | $482M+1.8% | |
| Life Science | $301.7M+4.3% | $289.3M-6.9% | $310.9M+0.4% | $309.8M+0.6% | $308.1M+7.5% | |
| Cost of goods sold by Business | ||||||
| Clinical Diagnostics | $181.8M-13.7% | $210.6M+8.7% | $193.7M+1.0% | $191.8M+7.0% | $179.2M-13.3% | |
| Life Science | $100.9M-26.6% | $137.4M+18.6% | $115.9M+1.2% | $114.5M+14.3% | $100.2M-15.7% | |
| Depreciation, Depletion and Amortization by Business | ||||||
| Clinical Diagnostics | $22.6M-1.3% | $22.9M-3.0% | $23.6M+3.5% | $22.8M+8.1% | $21.1M-3.2% | |
| Life Science | $18.3M-6.6% | $19.6M-4.9% | $20.6M+15.7% | $17.8M+4.7% | $17M-2.3% | |
| Goodwill by Business | ||||||
| Clinical Diagnostics | $421.8M0.0% | $421.8M+0.2% | $420.9M-0.2% | $421.6M+1.2% | $416.5M+1.0% | |
| Life Science | $490.5M-0.5% | $493.2M0.0% | $493M-0.4% | $495.2M+48.6% | $333.3M0.0% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Clinical Diagnostics | $0-100% | $900K— | $0-100% | $5.1M+24.4% | $4.1M+189% | |
| Life Science | -$2.7M— | —— | -$800K— | $0— | $0— | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | ||||||
| Clinical Diagnostics | $293.4M0.0% | $293.4M0.0% | $293.4M0.0% | $293.4M0.0% | $293.4M0.0% | |
| Life Science | $41.8M0.0% | $41.8M0.0% | $41.8M0.0% | $41.8M0.0% | $41.8M0.0% | |
| Goodwill, net by Business | ||||||
| Clinical Diagnostics | $128.4M0.0% | $128.4M+0.7% | $127.5M-0.5% | $128.2M+4.1% | $123.1M+3.4% | |
| Life Science | $448.7M-0.6% | $451.4M0.0% | $451.2M-0.5% | $453.4M+55.5% | $291.5M0.0% | |
| Goodwill, Period Increase (Decrease) by Business | ||||||
| Clinical Diagnostics | $0-100% | $900K— | $0-100% | $5.1M+24.4% | $4.1M+189% | |
| Life Science | -$2.7M-1,450% | $200K— | $0-100% | $161.9M— | $0— | |
| Net Sales by Geography | ||||||
| Americas | $45.1M+0.9% | $44.7M+12.3% | $39.8M-3.2% | $41.1M+3.3% | $39.8M-3.6% | |
| Asia Pacific | $110.4M-31.8% | $161.8M+33.7% | $121M-4.3% | $126.4M+21.4% | $104.1M-28.9% | |
| Europe | $206.8M-14.8% | $242.6M+9.2% | $222.2M+2.3% | $217.2M+8.7% | $199.8M-9.9% | |
| UNITED STATES | $229.8M-5.9% | $244.1M-9.6% | $270M+1.2% | $266.9M+10.4% | $241.7M-6.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Rad Laboratories, Inc. break its business down?
- Bio-Rad Laboratories, Inc. (BIO.B) reports net sales by business across 3 parts — All Other Segments, Clinical Diagnostics and Life Science. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Rad Laboratories, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Rad Laboratories, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
